Remdesivir anti-viral trial reports 'rapid recoveries' for severe hospitalised coronavirus patients with 'nearly all' discharged within a week and only two deaths out of 125

Coronavirus hopes were today raised after the anti-viral remdesivir was found to help critically-ill patients recover within a week.

University of Chicago Medicine recruited 125 people with COVID-19 as part of global clinical trials. Of those people, 113 had severe disease.

All the patients were treated with daily infusions of remdesivir, an experimental drug first touted to treat Ebola which has been in the making for ten years.

Most of the patients have been discharged after their symptoms eased over a week, and only two patients have died.

More